Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1652

1.

Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.

Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK.

Ophthalmology. 2009 Sep;116(9):1740-7. doi: 10.1016/j.ophtha.2009.05.033. Epub 2009 Jul 29.

PMID:
19643484
[PubMed - indexed for MEDLINE]
2.

Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration.

Rothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, Wolf-Schnurrbusch UE.

Am J Ophthalmol. 2009 May;147(5):831-7. doi: 10.1016/j.ajo.2008.12.005. Epub 2009 Feb 13.

PMID:
19217019
[PubMed - indexed for MEDLINE]
3.

Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.

Spielberg L, Leys A.

Graefes Arch Clin Exp Ophthalmol. 2010 Jul;248(7):943-56. doi: 10.1007/s00417-009-1256-6. Epub 2010 Mar 4.

PMID:
20204659
[PubMed - indexed for MEDLINE]
4.

An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.

Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M.

Am J Ophthalmol. 2007 Apr;143(4):566-83.

PMID:
17386270
[PubMed - indexed for MEDLINE]
5.

A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.

Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M.

Am J Ophthalmol. 2009 Jul;148(1):43-58.e1. doi: 10.1016/j.ajo.2009.01.024. Epub 2009 Apr 18.

PMID:
19376495
[PubMed - indexed for MEDLINE]
6.

A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.

Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG.

Ophthalmology. 2009 Sep;116(9):1731-9. doi: 10.1016/j.ophtha.2009.05.024. Epub 2009 Jul 29.

PMID:
19643495
[PubMed - indexed for MEDLINE]
7.

Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.

Kaiser PK, Blodi BA, Shapiro H, Acharya NR; MARINA Study Group.

Ophthalmology. 2007 Oct;114(10):1868-75. Epub 2007 Jul 12.

PMID:
17628683
[PubMed - indexed for MEDLINE]
8.

One-year results of intravitreal ranibizumab for neovascular age-related macular degeneration and clinical responses of various subgroups.

Kang S, Roh YJ.

Jpn J Ophthalmol. 2009 Jul;53(4):389-95. doi: 10.1007/s10384-009-0670-y. Epub 2009 Sep 8.

PMID:
19763757
[PubMed - indexed for MEDLINE]
9.

Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.

Cohen SY, Dubois L, Tadayoni R, Fajnkuchen F, Nghiem-Buffet S, Delahaye-Mazza C, Guiberteau B, Quentel G.

Am J Ophthalmol. 2009 Sep;148(3):409-13. doi: 10.1016/j.ajo.2009.04.001. Epub 2009 May 24.

PMID:
19477713
[PubMed - indexed for MEDLINE]
10.

Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration.

Lai TY, Chan WM, Liu DT, Lam DS.

Graefes Arch Clin Exp Ophthalmol. 2007 Dec;245(12):1877-80. Epub 2007 Sep 28.

PMID:
17901972
[PubMed - indexed for MEDLINE]
11.

Comparison of spectral-domain versus time-domain optical coherence tomography in management of age-related macular degeneration with ranibizumab.

Sayanagi K, Sharma S, Yamamoto T, Kaiser PK.

Ophthalmology. 2009 May;116(5):947-55. doi: 10.1016/j.ophtha.2008.11.002. Epub 2009 Feb 20.

PMID:
19232732
[PubMed - indexed for MEDLINE]
12.

Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.

Papadopoulou DN, Mendrinos E, Mangioris G, Donati G, Pournaras CJ.

Ophthalmology. 2009 Sep;116(9):1755-61. doi: 10.1016/j.ophtha.2009.03.017. Epub 2009 Jun 27.

PMID:
19560206
[PubMed - indexed for MEDLINE]
13.

A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.

Arias L, Ruiz-Moreno JM, Gómez-Ulla F, Fernández M, Montero J.

Retina. 2009 Nov-Dec;29(10):1444-9. doi: 10.1097/IAE.0b013e3181ae712d.

PMID:
19730163
[PubMed - indexed for MEDLINE]
14.

Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP).

Konstantinidis L, Mameletzi E, Mantel I, Pournaras JA, Zografos L, Ambresin A.

Graefes Arch Clin Exp Ophthalmol. 2009 Sep;247(9):1165-71. doi: 10.1007/s00417-009-1089-3. Epub 2009 Apr 29.

PMID:
19404661
[PubMed - indexed for MEDLINE]
15.

Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.

Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U.

Ophthalmology. 2009 Dec;116(12):2393-9. doi: 10.1016/j.ophtha.2009.05.039. Epub 2009 Oct 7.

PMID:
19815292
[PubMed - indexed for MEDLINE]
16.

Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.

Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A.

Retina. 2007 Apr-May;27(4):432-8.

PMID:
17420694
[PubMed - indexed for MEDLINE]
17.

Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial.

Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR; MARINA Study Group.

Arch Ophthalmol. 2007 Nov;125(11):1460-9.

PMID:
17998507
[PubMed - indexed for MEDLINE]
18.

Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.

Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, Dreyer RF, Gentile RC, Sy JP, Hantsbarger G, Shams N.

Ophthalmology. 2006 Apr;113(4):633.e1-4. Epub 2006 Feb 14.

PMID:
16483659
[PubMed - indexed for MEDLINE]
19.

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.

Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group.

Ophthalmology. 2009 Jan;116(1):57-65.e5. doi: 10.1016/j.ophtha.2008.10.018.

PMID:
19118696
[PubMed - indexed for MEDLINE]
20.

Effects of ranibizumab on exudative disciform scars.

Ahmad FK, Morley MG, Berry A, Wiegand TW, Heier JS, Morley EF, Sanguansak T, Topping TM, Frederick AR, Sang DN, Hughes MS, Cleary TS.

Ophthalmic Surg Lasers Imaging. 2009 Jul-Aug;40(4):366-72.

PMID:
19634740
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk